John-Paul Upton
Frontier Medicines (United States) · 12 works · 2,916 citations · h-index 8
Top works
- IRE1α Kinase Activation Modes Control Alternate Endoribonuclease Outputs to Determine Divergent Cell Fates
- IRE1α Induces Thioredoxin-Interacting Protein to Activate the NLRP3 Inflammasome and Promote Programmed Cell Death under Irremediable ER Stress
- IRE1α Cleaves Select microRNAs During ER Stress to Derepress Translation of Proapoptotic Caspase-2
- Caspase-2 Cleavage of BID Is a Critical Apoptotic Signal Downstream of Endoplasmic Reticulum Stress
- USP7 small-molecule inhibitors interfere with ubiquitin binding
- A kinase inhibitor activates the IRE1α RNase to confer cytoprotection against ER stress
- Analysis of endogenous Bax complexes during apoptosis using blue native PAGE: implications for Bax activation and oligomerization
- IRE1α Kinase Activation Modes Control Alternate Endoribonuclease Outputs to Determine Divergent Cell Fates
- Abstract B123: FMC-220, a highly potent and selective covalent activator of p53 Y220C, is broadly active in p53 Y220C containing PDX models across cancer indications
- Abstract 3787: Restoring the function of the guardian of the genome: FMC-220 a highly potent and selective covalent activator of p53 Y220C
- IRE1α Kinase Activation Modes Control Alternate Endoribonuclease Outputs to Determine Divergent Cell Fates
- Abstract SY23-03: Development and mechanistic characterization of USP7 deubiquitinase inhibitors